

Preface

Dear Colleagues,

In this edition, our objective is to shed light on various dimensions of inborn errors of immunity (IEI) by directing our attention to specific and relevant areas. This includes an exploration of the historical evolution of IEI, particularly from the perspective of its development in Turkey—a country with a longstanding tradition of studying these disorders. We examine distinct disease manifestations through reviews on pulmonary complications in monogenic CVID disorders and the consequences of SARS-CoV-2 infection in IEI patients. Additional reviews will tackle emerging molecular mechanisms in immune dysregulatory diseases, encompassing STAT1, STAT3, and STAT6 GOF diseases, LRBA deficiency, monogenic inflammatory bowel diseases, and primary atopic disorders. Our coverage extends to the latest advancements in immunoglobulin replacement therapy, focusing on new therapeutic formulations and their application in IEI. Overall, we anticipate that these reviews will prove insightful in highlighting the foundational concepts within the IEI domain, as well as showcasing the recent and noteworthy progress in this field.



Talal Chatila, M.D., M.Sc.

Denise and David Bunning Professor of Pediatrics Harvard Medical School Division of Immunology, Boston Children's Hospital, USA



Safa Baris, MD

Professor of Pediatrics Marmara University Medical Faculty Division of Pediatric Allergy and Immunology, Istanbul, Turkey